Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lieberman, A.
Right arrow Articles by Kleinberg, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lieberman, A.
Right arrow Articles by Kleinberg, D.
NEUROLOGY 1981;31:961
© 1981 American Academy of Neurology

Lisuride in Parkinson disease

Efficacy of lisuride compared to levodopa Abraham Lieberman, M.D., Menek Goldstein, Ph.D., Andreas Neophytides, M.D., Mark Kupersmith, M.D., Morton Leibowitz, M.D., Nina Zasorin, M.D., Russell Walker, M.D. and David Kleinberg, M.D.

Departments of Neurology (Drs. Lieberman, Neophytides, Kupersmith, Zasorin. and Walker), Psychiatry tDr Goldsteint, and Medicine (Drs. Kleinberg and Leibowitz), New York University School of Medicine. New York, NY.

Address correspondence and reprint requests to Dr. Lieberman, Professor of Neurology, 530 First Avenue, Suite 5A, New York, NY 10016.

Lisuride hydrogen maleate, a semisynthetic ergoline and potent central dopamine and serotonin agonist, was tested in 10 patients with moderate to marked Parkinson disease whose response to levodopa had diminished. In the group of 10 patients, there was a significant reduction (p =z 0.05) in bradykinesia, gait disorder, and total Parkinson disease disability score when levodopa was replaced with lisuride. The mean dose of lisuride was 3.6 mg per day. Among the 10 patients, 5 were better on lisuride than on levodopa, and 4 continue on lisuride 1 year later. A decline in efficacy was noted in all four after a mean of 45 months. Adverse effects necessitating discontinuing the drug were mental changes in three patients and nausea in one patient. Lisuride, when used alone, has definite antiparkinsonian activity and is a promising new drug.